Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fourth Quarter and Full Fiscal Year ended March 31, 2013 (FY13)
Business Overview: An integrated global pharmaceutical company operating through three main segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Major markets include India, North America, Russia-CIS, and Europe.
Key Financial Metrics
| Metric | FY13 (Rs. Mn) | FY12 (Rs. Mn) | Q4 FY13 (Rs. Mn) | Q4 FY12 (Rs. Mn) |
|---|---|---|---|---|
| Revenue | 116,266 | 96,737 | 33,400 | 26,584 |
| Gross Profit | 60,579 | 53,305 | 16,846 | 13,970 |
| Gross Margin | 52.1% | 55.1% | 50.4% | 52.6% |
| EBITDA | 27,820 | 25,409 | 9,293 | 6,798 |
| EBITDA Margin | 24.0% | 26.3% | 27.8% | 25.6% |
| Profit After Tax (PAT) | 16,776 | 14,262 | 5,709 | 3,427 |
| Diluted EPS (Rs.) | 98.44 | 83.81 | 33.51 | 20.14 |
| Cash & Equivalents | 22,099 | 18,152 | - | - |
| Total Borrowings | 36,760 | 32,210 | - | - |
Note: FY13 PAT figures in the press release (17.5 billion) are adjusted for impairment of intangibles/goodwill. The audited income statement shows PAT of 16,776 million.
Material Changes vs. Prior Period
- Revenue Growth: FY13 revenue grew 20% year-over-year (YoY). Excluding the one-time benefit of olanzapine exclusivity in FY12, organic growth was 26%. Q4 FY13 revenue grew 26% YoY.
- Profitability: PAT grew 18% YoY for the full year and 67% YoY for Q4. The Q4 surge was significantly aided by the absence of impairment charges that impacted Q4 FY12.
- Segment Performance:
- Global Generics: Revenue grew 18% YoY, driven by North America (19% growth) and Emerging Markets (31% growth).
- PSAI: Revenue grew 29% YoY due to increased sales to generic customers and higher custom pharmaceutical orders.
- Impairment Charges: FY12 included significant write-downs of intangible assets (Rs. 1,040 Mn) and goodwill (Rs. 181 Mn). FY13 saw minimal impairment (Rs. 507 Mn for intangibles, Rs. 181 Mn for goodwill), contributing to improved net margins.
- One-Time Income: The company received a settlement of Rs. 12,200 lakhs (USD 22.5 Mn) from Nordion Inc. regarding a breach of service agreement, recorded as other income and R&D cost reduction.
Guidance, Outlook, and Risks
- Product Pipeline: Launched 78 new generic products in FY13 and 18 in Q4. Filed 56 new product registrations and 47 DMFs globally during the year.
- US Market Strategy: 65 ANDAs pending with the USFDA, including 38 Paragraph IV filings and 8 with "First To File" status. Key growth drivers include limited competition products (e.g., ziprasidone, fondaparinux) and the Shreveport facility ramp-up.
- Dividend: The Board recommended a final dividend of Rs. 15 per share, subject to shareholder approval.
- Risks and Contingencies:
- Forward-looking statements are subject to risks including changes in global economic conditions, market acceptance of products, and regulatory approvals.
- Exposure to foreign exchange fluctuations (noted impact on SG&A expenses due to rupee depreciation).
- Impairment risks related to product-related intangibles and goodwill, as seen in previous periods.
Investor Verification Checklist
- Adjusted vs. Reported PAT: Verify the reconciliation between the press release PAT (adjusted for impairment) and the audited financial statement PAT.
- Olanzapine Impact: Confirm the specific revenue contribution of olanzapine in FY12 to accurately assess organic growth rates.
- Impairment Trends: Review the specific assets subject to impairment in FY13 (Rs. 507 Mn intangibles) to assess future risk exposure.
- Regulatory Pipeline: Monitor the approval status of the 65 pending ANDAs, particularly the 38 Paragraph IV filings, as these are critical for future US revenue.
- Debt Levels: Note the increase in total borrowings from Rs. 32,210 Mn to Rs. 36,760 Mn and assess the impact on interest coverage.